Andrew Phimister
Head of Formulations

Andrew is a pharmaceutical scientist with over 20 years of experience in formulation development, drug delivery, and business development. He lead R&D teams for Novartis Pharmaceuticals, focused on profiling and formulating early-stage small molecules and advancing leads into clinical development.

He developed expertise in technologies for delivering poorly soluble drugs, injectable depot formulations, and novel drug delivery approaches, like tumor targeting and oral peptide delivery. Later, as US head of Drug Product BD for STA/Wuxi, a Chinese CDMO, Andrew helped expand the pharmaceutical group several fold and add new formulation technologies.

Andrew is now working as a pharmaceutical consultant supporting early-stage pharmaceutical companies in areas such as oncology, fibrosis, neurological diseases and ophthalmology.